These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 7525042)

  • 21. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
    Teodorovic I; Pittaluga S; Kluin-Nelemans JC; Meerwaldt JH; Hagenbeek A; van Glabbeke M; Somers R; Bijnens L; Noordijk EM; Peeters CD
    J Clin Oncol; 1995 Nov; 13(11):2819-26. PubMed ID: 7595744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [COP-BLAM III regimen for elderly non-Hodgkin's lymphoma].
    Niitsu N; Umeda M; Shirai T
    Nihon Ronen Igakkai Zasshi; 1993 Sep; 30(9):753-8. PubMed ID: 7693992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-Hodgkin's lymphoma in Saudi Arabia: prognostic factors and an analysis of the outcome of combination chemotherapy only, for both localized and advanced disease.
    Ibrahim EM; Satti MB; Al-Idrissi HY; Al-Mulhim FA; Abssod GH; Abdel Jabar A
    Eur J Cancer Clin Oncol; 1988 Mar; 24(3):391-401. PubMed ID: 2454821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
    Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
    Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
    Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
    Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Weekly CHOP chemotherapy in the treatment of intermediate-grade non-Hodgkin's lymphomas--cooperative group study by seven institutes].
    Kobayashi M; Sao H; Mizuta S; Kamiya O; Ohara K; Nagata K; Takeyama H; Watanabe E; Yamada H; Mizuno H
    Rinsho Ketsueki; 1990 Oct; 31(10):1656-63. PubMed ID: 2255056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
    Kluin-Nelemans HC; Zagonel V; Anastasopoulou A; Bron D; Roozendaal KJ; Noordijk EM; Musson H; Teodorovic I; Maes B; Carbone A; Carde P; Thomas J
    J Natl Cancer Inst; 2001 Jan; 93(1):22-30. PubMed ID: 11136838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.
    Somers R; Carde P; Thomas J; Tirelli U; Keuning JJ; Bron D; Delmer A; de Bock R; De Wolf-Peeters C; Keunig JJ
    Ann Oncol; 1994; 5 Suppl 2():85-9. PubMed ID: 7515651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
    Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
    Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COPP chemotherapy for elderly patients with intermediate and high grade non-Hodgkin's lymphoma.
    Liang R; Todd D; Chan TK; Chiu E; Lie A; Ho F
    Hematol Oncol; 1993; 11(1):43-50. PubMed ID: 7686880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
    Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
    Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
    Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
    J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.